Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective

References

• Ahmed KA, Muniandy S, Ismail IS. Type 2 diabetes and vascular complications: a pathophysiologic view. Biomed Res 2010;21:147-55
   Web of Science ®Google Scholar
• Hayes AJ, Leal J, Gray AM, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013;56:1925-33
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas sixth edition. 2014. http://www.idf.org/sites/default/files/Atlas-poster-2014_EN.pdf. Accessed November 12, 2015
   Google Scholar
• Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabetes Med 2012;29:855-62
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care 2015;38:140-9
   PubMed Web of Science ®Google Scholar
• DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide). Diabetes Technol Ther 2011;13:1145-54
   PubMed Web of Science ®Google Scholar
• Grimm M, Han J, Weaver C, et al. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. Postgrad Med 2013;125:47-57
   PubMed Web of Science ®Google Scholar
• Kayaniyil S, Lozano-Ortega G, Bennett HA, et al. A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus. Diabetes Therapy 2016;7:27-43
   PubMed Web of Science ®Google Scholar
• EMA. Bydureon. Summary of product characteristics. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf. Accessed December 10, 2015
   Google Scholar
• National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. 2015. http://www.nice.org.uk/guidance/ng28. Accessed December 10, 2015
   Google Scholar
• Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. J Am Med Assoc 2010;303:1410-18
   PubMed Web of Science ®Google Scholar
• Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes. A population-based study of health service resource use. Diabetes Care 2003;26:1176-80
   PubMed Web of Science ®Google Scholar
• Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006;82:280-4
   PubMed Web of Science ®Google Scholar
• Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 2009;12:409-18
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Wilke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II – An ISPOR good research practices task force report. Value Health 2015;18:161-72
   PubMed Web of Science ®Google Scholar
• McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab 2010;12:623-30
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. http://www.nice.org.uk/article/pmg9. Accessed November 13, 2015
   Google Scholar
• National Institute of Health and Care Excellence. Appendix F: Full Health Economics Report. type 2 diabetes in adults: management. draft for consultation. 2015. http://www.nice.org.uk/guidance/gid-cgwave0612/documents/type-2-diabetes-appendix-f2. Accessed November 13, 2015
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
   PubMed Web of Science ®Google Scholar
• Henry RR, Klein EJ, Malloy J, et al. DURATION-1 extension: efficacy and tolerability of exenatide once weekly over 6 years in patients with T2DM. Diabetes 2014;63(suppl 1):A247
   Google Scholar
• Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol 2014;2:464-73
   PubMed Web of Science ®Google Scholar
• Alva M, Gray A, Mihaylova B, et al. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabetes Med 2015;32:459-66
   Web of Science ®Google Scholar
• PSSRU. Unit costs of health & social care. 2014. http://www.pssru.ac.uk/project-pages/unit-costs/2014. Accessed November 13, 2015
   Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Mak 2002;22:340-9
   PubMed Web of Science ®Google Scholar
• Currie CJ, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005;8:581-90
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
   PubMed Web of Science ®Google Scholar
• Lane S, Levy A, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin 2014;30:1267-73
   PubMed Web of Science ®Google Scholar
• Counterweight Project Team. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care. J Health Serv Res Policy 2008;13:158-66
   PubMed Web of Science ®Google Scholar
• Samyshkin Y, Guillermin AL, Best JH, et al. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. J Med Econ 2012;15(Suppl 2):6-13
   PubMedGoogle Scholar
• Fonseca T, Clegg J, Caputo G, et al. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain. J Med Econ 2013;16:926-38
   PubMedGoogle Scholar
• Beaudet A, Palmer JL, Timlin L, et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ 2011;14:357-66
   PubMedGoogle Scholar
• Guillermin A, Lloyd A, Best J, et al. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. J Med Econ 2012;15:654-63
   PubMedGoogle Scholar
• Wang B, Roth JA, Nguyen H, et al. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States. PLoS One 2015;10:e0121915
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013;381:117-24
   PubMed Web of Science ®Google Scholar
• Scott DA, Boye KS, Timlin L, et al. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab 2013;15:213-23
   PubMed Web of Science ®Google Scholar
• The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638-46
   PubMed Web of Science ®Google Scholar
• Granström O, Bergenheim K, McEwan P, et al. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Prim Care Diabetes 2012;6:127-36
   PubMed Web of Science ®Google Scholar
• Scottish Medicine Consortium. Dapagliflozin for the Treatment of Type 2 Diabetes, 2014. http://www.scottishmedicines.org.uk/SMC_Advice/Advice/799_12_dapagliflozin_Forxiga/Briefing_note_dapagliflozin_Forxiga_Resubmission. Accessed November 13, 2015
   Google Scholar
• Cummins E, Scott N, Rothnie K, et al. Evidence Review Group report; dapagliflozin for the treatment of type 2 diabetes. Aberdeen HTA Group, 2013. http://www.nice.org.uk/guidance/ta288. Accessed November 13, 2015
   Google Scholar
• National Institue of Health and Care Excellence. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes, 2012. http://www.nice.org.uk/guidance/ta248. Accessed November 13, 2015
   Google Scholar
• National Institute of Health and Care Excellence. Liraglutide for the treatment of type 2 diabetes mellitus, 2010. http://www.nice.org.ul/guidance/ta203. Accessed November 13, 2015
   Google Scholar
• National Institute for Health and Clinical Excellence. NICE clinical guideline 87. Type 2 diabetes: the management of type 2 diabetes, 2009. http://www.nice.org.uk/guidance/cg87. Accessed November 13, 2015
   Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28
   PubMed Web of Science ®Google Scholar
• Baboolal K, McEwan P, Sondhi S, et al. The cost of renal dialysis in a UK setting—a multicentre study. Nephrol Dial Transplant 2008;23:1982-9
   PubMed Web of Science ®Google Scholar
• Hammer M, Lammert M, Mejías SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12:281-90
   PubMedGoogle Scholar